Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of rituximab (Roche Products) to submit evidence of the clinical and cost effectiveness of rituximab in combination with corticosteroids for treatment of an...
Những tác giả chính: | Latimer, N, Carroll, C, Wong, R, Tappenden, P, Venning, M, Luqmani, R |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
Springer International Publishing
2014
|
Những quyển sách tương tự
-
Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.
Bằng: Latimer, N, et al.
Được phát hành: (2014) -
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
Bằng: Guerry, M, et al.
Được phát hành: (2012) -
Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
Bằng: Flossmann, O, et al.
Được phát hành: (2006) -
Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis
Bằng: Michael A Paley, et al.
Được phát hành: (2019-01-01) -
Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
Bằng: Robson, J, et al.
Được phát hành: (2017)